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Abstract
It remains challenging to accurately predict whether an individual arteriovenous ﬁstula (AVF) will
mature and be useable for haemodialysis vascular access. Current best practice involves the use of
routine clinical assessment and ultrasonography complemented by selective venography and
magnetic resonance imaging. The purpose of this literature review is to describe current practices
in relation to pre-operative assessment prior to AVF formation and highlight potential areas for
future research to improve the clinical prediction of AVF outcomes.
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Introduction
It remains challenging to accurately predict whether an
individual arteriovenous ﬁstula (AVF) will mature and be
useable for haemodialysis vascular access. In part, this is
due to the heterogeneity of end-stage renal disease
(ESRD) populations studied as these have varied in terms
of age structure, background ethnicity and the relative
prevalence of different ESRD aetiologies. The natural
history of AVF maturation is also confounded by multiple
comorbid conditions, such as diabetes and peripheral
vascular disease, which may be present in ESRD patients.
The outcome (clinically usable AVF) is further impacted by
variation in point-of-care management of AVFs, e.g. can-
nulation expertise. In order to study the effect any variable
has on a given vascular access outcome, it is important to
establish speciﬁc deﬁnitions. The fact that there are mul-
tiple deﬁnitions of vascular access outcomes (summarized
in Table 1) makes it more difﬁcult to compare published
data from different centres and countries.
The Renal Association Vascular Access for Haemodialy-
sis clinical practice guidelines [1] have encouraged the
earlier formation of AVFs in an attempt to reduce the
number of ESRD patients commencing haemodialysis
using a central venous catheter (CVC). Furthermore, in the
UK, National Health Service best practice tariffs for
haemodialysis promote the use of AVFs as renal units pro-
viding haemodialysis receive higher annual payments for
those ESRD patients using an AVF (compared with patients
with a CVC). These ﬁnancial incentives coupled with the
persistently high failure rate of AVFs support renewed
efforts to identify pre-operative predictors of AVF out-
comes. The purpose of this literature review is to describe
current practices in relation to pre-operative assessment
prior to AVF formation as summarized in Figure 1 and
highlight potential areas for future research to improve
the clinical prediction of AVF outcomes.
How an AVFmatures
Guidelines suggest attempting to create an AVF at the
most appropriate distal arm site. In practice, this means
choosing the more proximal radiocephalic site before con-
sidering a brachiocephalic AVF. If these sites are unsuit-
able then a brachiobasilic procedure or placement of an
arteriovenous graft (AVG) may be most appropriate [1].
A useable AVF can offer the haemodialysis patient a
durable vascular access option which, in comparison to
prolonged CVC dependence, is associated with a lower risk
of bloodstream infection and central venous stenosis [2].
The ideal AVF must achieve an adequate connection
between the high-pressure arterial and low-pressure
venous systems; bypassing the small capillary network of
the palmar arch while maintaining arterial perfusion and
venous drainage in the tissues distal from the site of cre-
ation [3]. As a result of the arteriovenous anastomosis,
pressure within the vein increases, causing dilatation and
‘arterialization’ of the anastomosed vein. A reﬂex increase
in cardiac output allows for this distal tissue perfusion and
maturation of the ﬁstula which is frequently complemen-
ted by retrograde arterial ﬂow [4]. Where retrograde ﬂow
is excessive, steal syndrome may occur characterized by
distal neuralgia and eventually peripheral limb ischaemia
[5, 6].
Poiseuille’s law [as shown in Equation (1)] describes
essential determinants of blood ﬂow which are related to
perfusion pressure, blood vessel radius and length and the
viscosity of blood. The maturation of an AVF is partly
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governed by these parameters.
Volume flow rate ¼ Pressure difference Radius
4
ð8=pÞ  Viscosity Length ð1Þ
Normal brachial arterial blood ﬂow is 50 mL/min with
radial blood ﬂow rates of 25 mL/min [7]. This blood ﬂow
rate has been shown to increase 3- to 5-fold during exer-
cise or following reactive hyperaemia; however, according
to Poiseuille’s law, radial artery ﬂow must increase 20-fold
in order to deliver >500 mL/min of blood ﬂow and achieve
radiocephalic AVF maturation. The actual measured
increase in blood ﬂow is only 40–50% of this prediction
and therefore other mechanisms must be operating [8].
The increase in blood ﬂow is achieved through increased
antegrade arterial blood ﬂow in addition to retrograde
blood ﬂow from the palmar arterial arch in ∼75% of AVFs
[4], decreased blood viscosity associated with the increase
in ﬂow rate and therefore reduction in wall shear stress
and friction [8]. This occurs in combination with main-
tained antegrade ﬂow throughout the cardiac cycle as
opposed to retrograde ﬂow seen in diastole in a normal
artery [9].
Other processes are involved in AVF maturation as
shown in Figure 2. Arterial disease in the form of arterio-
sclerosis and pre-existing neointimal thickening asso-
ciated with conditions such as diabetes, hypertension and
ESRD itself may contribute to the development of neointi-
mal hyperplasia after AVF formation [10]. Endothelial dys-
function can also impair the arterial response to increased
wall shear stress, therefore inhibiting the dilatation and in-
creased ﬂow rates required for AVF maturation [3]. Venous
trauma and ﬁbrosis caused by previous cannulation, vene-
puncture and the surgical creation of an AVF can lead to
inability of venous distension preventing ﬂow-induced re-
modelling [11]. Pre-existing arterial or venous disease and
the surgical procedure itself are important components of
the success or failure of an AVF.
The effect of coagulation disorders (high factor VIII:C,
homocysteine, ﬁbrinogen, d-dimer; presence of antiphospho-
lipid antibodies and short thrombin time) and thrombophilia
(factor V Lieden and prothrombin G20210A mutations;
protein C and antithrombin activities; and protein S) on mat-
uration is unknown, although female sex and thrombophilia
are independent risk factors for loss of primary patency [12].
A recent Cochrane systematic review on the use of
antiplatelet agents in chronic kidney disease found that
while there was an associated reduction in early thrombosis
rates of AVF, this had no effect on suitability for dialysis sup-
porting other underlying reasons [13]. For the purposes of
pre-operative evaluation, the presence of such factors may
be important but are generally not modiﬁable or useful in in-
dividuals to plan access.
Pre-operative assessment
Clinical assessment
Clinical assessment of an ESRD patient’s suitability for AVF
creation involves detailed history taking and appropriate
physical examination as summarized in Table 2. The use of
clinical assessment alone may provide sufﬁcient assess-
ment in selected cases. Wells et al. [14] discuss the select-
ive use of ultrasonographic vascular mapping in the
evaluation of patients prior to the start of haemodialysis.
They indicate that for some patients, ultrasound vascular
mapping is unnecessary and allows patients to avoid any
time delay associated with an extra clinic appointment for
ultrasonography and also reduces overall costs associated
with preoperative assessment. They suggest that this facil-
itates the development of a ‘one stop shop’ whereby
patients undergo clinical assessment and surgery on the
same day. It could also be argued that training of vascular
access surgeons in the use of ultrasonographic techniques
speciﬁc to vascular access would also reduce the costs
incurred and time delays.
Patient and ﬁstula selection
Age and gender are often natural discriminators. As with
many conditions, the average age of the population with
ESRD is increasing annually. Hod et al. [15] highlighted
that the important risk factors for AVF failure in those
older than 67 years of age are increasing age, female
gender, black race, diabetes, cardiac failure and a shorter
period of pre-ESRD nephrology care. Similarly, Miller et al.
[16] have shown a lower AVF adequacy in women com-
pared with men which was unexplained by pre-operative
blood vessel diameters. Ng et al. [17] found from their
analysis of 2920 patients that AVGs, female gender, dia-
betes and advanced age were all associated with signiﬁ-
cantly shorter primary AVF patency.
Table 1. Deﬁnitions of ﬁstula outcomes




This is an AVF for which, despite interventions (radiologic or surgical), it was not possible




This is an access for which, despite interventions (radiologic or surgical), it was not
possible to use the AVF successfully for haemodialysis by the sixth month following its
creation (NAVAC deﬁnition)
Primary patency The interval from the time of access creation until the ﬁrst access thrombosis or any intervention to maintain or
restore blood ﬂow (NAVAC and SVS deﬁnition)
Assisted primary patency
(thrombosis-free access survival)
The interval from time of access placement to access thrombosis or time of measurement of patency, including
intervening manipulations (surgical or endovascular interventions) designed to maintain the functionality of a
patent access (not recommended by NAVAC or SVS)
Functional primary patency The time from the ﬁrst successful two-needle cannulation until the ﬁrst intervention or access failure
Secondary (cumulative) patency The time from access creation until access abandonment. Secondary patency was not terminated by surgical or
interventional radiology procedures to maintain or restore patency (NAVAC and SVS deﬁnition)
Functional secondary patency The interval from the ﬁrst successful two-needle cannulation for haemodialysis treatment to access
abandonment (NAVAC and SVS deﬁnition)
AVF, arteriovenous ﬁstula; NAVAC, North American Vascular Access Consortium; SVS, Society for Vascular Surgery.
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In a systematic review performed by Al-Jaishi et al., it
was shown that the primary AVF failure rates were higher
in more distal compared with proximal upper limb sites
[primary failure rates of 28% for lower arm AVF and 20%
for upper arm AVF (P = 0.001)]. Similarly, the primary AVF
patency rates at 1 year were signiﬁcantly worse in lower
arm versus upper arm sites (55 versus 65% for lower and
upper arm AVFs, respectively) [18].
Older age, female gender, presence of diabetes and
distal AVFs have all been identiﬁed as risk factors for
Fig. 1. Summary of advantages and disadvantages associated with preoperative assessment tools. DSA, digital subtraction angiography; MRV, magnetic
resonance venography; DUS, Doppler ultrasound scan; MRI, magnetic resonance imaging; NSF, nephrogenic systemic ﬁbrosis; ESRD, end-stage renal
disease; AGE, advanced glycation end-products.
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primary AVF failure and should be taken into consideration
when planning an AVF procedure.
Doppler ultrasound
Doppler ultrasound (DUS) is one of the key techniques
currently employed for enhancing clinical examination of
the patient prior to AVF construction. This is used not only
as a preoperative tool in assessing arterial and venous
anatomy but also in post-operative monitoring of AVF mat-
uration and ongoing AVF surveillance. DUS assessment
does require more clinical skill, equipment and time to
perform (compared with clinical examination alone), but it
remains non-invasive, safe, has reproducible results and
helps to identify clinically occult veins [19]. DUS allows for
observation of arterial diameter, vessel wall thickness, wall
alterations, blood vessel course, localization of any ob-
structive or stenotic lesions present and can also perform a
functional assessment. The 2007 European Renal Best Prac-
tice guidelines suggest the use of DUS assessment in all pa-
tients being considered for vascular access formation [20].
A number of studies have been conducted to assess the
utility of arterial diameter in predicting AVF outcomes.
Malovrh [21] reported immediate AVF failure rates of 44%
and early failure rates of 64% where radial arterial dia-
meters were <1.5 mm on pre-operative DUS. This con-
trasts with immediate and early AVF failure rates of 8 and
17%, respectively, where radial arterial diameters were
>1.5 mm [22]. These ﬁndings have been supported by
Parmar et al. [22] who found arterial diameters of <1.5
mm had an AVF failure rate of 45% compared with 0%
when radial arterial diameter was >1.5 mm. Wong et al.
[23] found a signiﬁcant difference at an arterial diameter
cut-off of 1.6 mm. Silva et al. [24] proposed a cut-off of 2
mm for arterial diameter as they found this to be asso-
ciated with a very low early AVF failure rate of 8% and an
excellent 1-year AVF patency rate of 83%. AVF patency
beyond 6 weeks is considered an important parameter in
the analysis of AVF outcomes.
DUS can be used to assess the functional ability of the
artery to dilate by using a reactive hyperaemia test. This is
performed by asking the patient to clench their ﬁst while
observing the phasic ﬂow via DUS. The patient then re-
leases the ﬁst and the arterial ‘reaction’ is measured. This
simulates the change from high pressure to low pressure
which occurs in AVF formation and therefore provides a
surrogate measurement of how the artery will respond to
the ‘stress’ of AVF surgery. Malovrh [19] demonstrated that
an absence of reactive hyperaemia characterized by a re-
sistance index of <0.7 on opening of the ﬁst is predictive of
immediate postoperative AVF failure. These ﬁndings have
been challenged by Lockhart et al. [25] who found no dif-
ference in AVF outcomes, except in functional patency of
AVFs in women and Wall et al. [26] who found no differ-
ence in primary functional AVF patency but a signiﬁcant
difference in secondary AVF patency following surgical re-
vision. These studies do not lend themselves to direct
comparison but do suggest that the ability of the artery to
dilate plays a signiﬁcant functional role in AVFmaturation.
DUS is also used to assess the cephalic and basilic veins
in the arm, including the venous wall, route, patency,
calibre, distensability and collateral circuits. The ideal vein
for AVF formation has a relatively straight course and
should lie <6 mm from the skin surface [27].
Due to the superﬁcial nature of the veins, transducer gel
should be applied copiously to prevent excessive pressure
on the vein in question and therefore underestimation of
vein diameter. Several studies have suggested the ideal
diameter of the vein to be used for AVF formation. Small
veins of <1.6 mm in diameter are associated with a high
risk of early AVF failure within 12 weeks [23]. Silva et al.
[24] suggested a minimum diameter of 2.5 mm with a
tourniquet applied, whereas Mendes et al. [28] suggest a
minimum diameter of >2 mm.
Venous distensability is assessed by measuring the
diameter of the vein before and after at least 2 min of
tourniquet placement. This can be achieved by inﬂating a
sphygmomanometer to 60 mmHg. The percentage in-
crease in the size of the vein is then evaluated by ultra-
sound. Malorvh [29] found that venous distensability was
predictive of outcomes since subsequently successful AVFs
showed a mean percentage dilatation of 44% compared
with only 11% in the unsuccessful AVF group. Lockhart
et al. [30] similarly found DUS useful in the identiﬁcation
of suitable veins by concluding that veins with a luminal
diameter of >2.5 mm and those smaller veins that dilated
up to 2.5 mmwith placement of a tourniquet were equally
Table 2. Summary of clinical assessment prior to arteriovenous ﬁstula
formation
Clinical assessment for vascular access
History Previous central venous
catheterization
Presence of diabetes and
hypertension
Use of anticoagulant or antiplatelet
agents
Peripheral arterial assessment Palpation of axillary, brachial, radial
and ulnar pulses bilaterally noting
presence, absence or diminished
character






Assess cephalic and basilic systems
Assess for patency, presence of a
linear segment, collateral
engorgement of chest wall veins
Fig. 2. Summary of factors involved in AVFmaturation.
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suitable for AVF formation. The presence of accessory
veins has also been suggested to be a factor in non-mat-
uration of AVF. An accessory vein <5 cm from the anasto-
mosis can alter the functionality of the AVF [23], while the
size of the collaterals rather than their position may
impact on the rate of AVF non-maturation [31].
A recent systematic review [32] has concluded that the
use of pre-operative DUS is associated with a higher rate of
commencing dialysis, but this association did not reach
statistical signiﬁcance and therefore additional novel pre-
dictors of AVFoutcomesmay help improve clinical manage-
ment of ESRD patients. This systematic review conclusion
is supported by Smith et al. [33] who randomized patients
into either routine or selective preoperative ultrasound
imaging. They reported that routine pre-operative does not
reduce early failure rates, inﬂuence site of AVF formation or
reduce complications concluding that routine preoperative
imaging may not be necessary where clinical evaluation
detects suitable anatomy for AVF formation.
A novel computational model has been suggested by
Caroli et al. [34] which is completely automated, fast, in-
volves operator-independent calculations and enables the
observer to quantitatively estimate patient-speciﬁc post-
operative blood ﬂow volume change over different AVF
conﬁgurations. This model uses preoperative vessel di-
mension and arterial blood ﬂow volume measurements
taken during ultrasound assessment as input parameters
to predict postoperative diameters and blood ﬂow volumes
at different time points after surgery. The computational
model was found to be accurate in predicting blood ﬂow
volumes in individual patients 40 days postoperatively
with highly signiﬁcant correlation for different AVFs. As
Roy-Chaudhury et al. [35] comment, this is a step towards
individualization of AVF creation and a good example of
the multidisciplinary research collaboration necessary to
achieve a signiﬁcant impact on vascular access outcomes.
Venography
Digital subtraction venography is considered to be the gold
standard for assessment of the venous system and has
been investigated as a potential adjunct to pre-operative
assessment of patients with ESRD referred for AVF forma-
tion. Traditional iodinated contrast can be used in patients
who are being dialysed; however, in patients who are pre-
dialysis, magnetic resonance venography had been shown
to have acceptable sensitivity and speciﬁcity when com-
pared with venography with good inter-observer correlation
regarding imaging quality and strategy planning [36].
Gadolinium-based magnetic resonance contrast media are
no longer considered safe for persons with chronic kidney
disease because of the risk of nephrogenic systemic ﬁbrosis
[37]. Carbon dioxide-based venography is a promising alter-
native contrast choice for use in patients with advanced
chronic kidney disease and ESRD [38].
Hyland et al. [39] have shown that venography is able to
identify clinically occult veins which may be usable for AVF
formation, a conclusion which is supported by Patel et al.
[40] who found that while this imaging modality can iden-
tify a greater number of suitable veins, paradoxically, the
combined use of DUS and venography was associated with
a decreased AVF maturation rate. The 2007 European Best
Practice Guidelines advocate central venous imaging for all
patients with a history of CVC placement to identify central
venous stenosis or occlusion prior to AVF formation [21].
Magnetic resonance imaging
Magnetic resonance angiography (MRA) has been shown
to enable accurate detection of upper limb arterial and
venous stenosis and occlusions prior to AVF creation [41].
These stenoses are undetectable by conventional DUS
and therefore identiﬁcation could potentially reduce the
early AVF failure and non-maturation rate. The recognition
of nephrogenic systemic ﬁbrosis and its association with
gadolinium-based contrast media has prompted compari-
son of contrast-enhanced versus non-contrast-enhanced
MRA [42] (NCE-MRA) and shown that while image quality
and vessel-to-background ratios were lower, NCE-MRA is a
feasible alternative in patients with ESRD.
Merkx et al. [43] assessed the merits of NCE-MRA for pre-
dicting vascular access outcomes based around a com-
puter model. Postoperative arm inﬂows were predicted by
computer modelling following pre-operative NCE-MRA and
compared with blood ﬂow measurements assessed by DUS
postoperatively. They concluded that NCE-MRA is able to
provide geometrical details of arterial stenoses which could
assist the vascular surgeon in AVF planning. This expensive
and less readily available investigation is unlikely to replace
clinic-based DUS in the assessment of patients for AVF for-
mation but may have applications in patients with periph-
eral arterial disease, thrombosis or reduced arm inﬂows
due to local stenoses or global narrowing within the arterial
lumen. Another limitation of this method is the necessity
for DUS assessment of venous diameters since NCE-MRA
grossly overestimates venous diameters [44].
Novel techniques for prediction of AVF outcomes
Assessment of arterial stiffness
Arterial stiffness, which is common in patients with chronic
kidney disease, refers to the distensability, compliance and
elastic modulus of the arterial vascular system and can be
measured locally, regionally and systemically. Aortic pulse
wave velocity is considered the gold standard [45] for
assessing arterial stiffness as it gives the clearest patho-
physiological signiﬁcance since the majority of the buffer-
ing of pulse waves occurs within the aorta. The pulse wave
Vicorder™ (Smart Medical, Moreton-in-Marsh, UK) is a non-
invasive, easy to learn and reproducible method of asses-
sing stiffness along an arterial section. Although other
systems exist to measure aortic pulse wave velocity such
as the SphygmoCor™ system (AtCor Medical, West Ryde,
NSW, Australia) and Complior™ apparatus (Artech Medical,
Pantin, France), these require greater operator instruction
and are more intrusive to patients as they require palpation
and assessment at the femoral artery. Increased aortic
pulse wave velocity has been independently associated
with adverse cardiovascular outcomes in large prospective
studies, including speciﬁcally patients with ESRD [46]. As-
sessment of arterial stiffness has yet to be extensively in-
vestigated in relation to AVF outcomes and is an area of
interest for future research projects.
Assessment of endothelial function
The responsiveness of the endothelium is an important
aspect of the remodelling required to establish a mature
AVF. The endothelium acts as an interface between the
blood and all other tissues in the body performing import-
ant roles in maintaining the vascular environment through
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release of agents that regulate vasomotor tone, inﬂamma-
tory responses and homeostatic functions [46]. Nitric oxide
is a potent vasodilator, inhibitor of inﬂammatory activity,
smooth muscle cell proliferation and platelet adhesion and
aggregation [47]. The loss of the vasodilatory response and
promotion of thrombosis, inﬂammation and cellular prolif-
eration associated with endothelial dysfunction is a poten-
tially worthwhile research topic, since these mechanisms
are closely related to AVF maturation. A number of studies
have linked endothelial dysfunction with uraemia and
reduced nitric oxide production in chronic renal disease
[48]. Owens et al. [49] found evidence that impairment of
endothelial function is associated with decreased arterial
remodelling and ﬁnal venous diameter attained at 3
months post-ﬁstula formation.
Two methods of measuring endothelial dysfunction are
ﬂow-mediated dilatation (FMD) and peripheral arterial to-
nometry (PAT). FMD is the most well-established method
of assessing endothelial function and is based on the
reactive hyperaemic response following a period of occlu-
sion with a tourniquet. Increased blood ﬂow following
release of the cuff causes increased wall shear stress,
leading to release of nitric oxide and therefore vasodilata-
tion [50]. Monitoring the response will give a surrogate
marker of endothelial performance post-ﬁstula formation
and therefore guide vascular surgeons regarding patient
suitability and vascular access site placement. PAT is a
more recent development which uses pneumatic ﬁnger
probes to measure the digital pulse wave amplitude when
reactive hyperaemia is induced [51]. A recent study asses-
sing the correlation between these two methods in
healthy patients and patients with peripheral arterial
disease concluded that there was no correlation between
these two methods and that FMD is a more accurate
measure of nitric oxide-induced endothelial function [52].
A novel method of assessing the hyperaemic response
in patients undergoing AVF formation is the use of near-in-
frared spectroscopy. This is a non-invasive, continuous,
real-time determination of chromophore concentration
on the basis of spectrophotometric principles. In mamma-
lian tissue, there are three chromophores which demon-
strate absorption spectra in the near-infrared range (800–
1200 nm wavelength), namely haemoglobin and deoxy-
haemoglobin, myoglobin and cytochrome oxidase. The
result is a measurement of mixed arterial and venous
oxygen concentrations within the tissue being studied
which, if placed distal to the site of AVF planning, may
provide new information about the physiological response
to AVF formation and assist in AVF planning. Another alter-
native way to assess endothelial dysfunction is the use of
laser Doppler ﬂowmetry and imaging to measure cutane-
ous perfusion accompanied by iontophoresis of acetylcho-
line and sodium nitroprusside. Hansell et al. [53] found a
signiﬁcant correlation between FMD in the brachial artery
and laser Doppler ﬂowmetry in small cutaneous vessels
supporting the systemic nature of endothelial dysfunction
and that microvascular changes in the skin mimic macro-
vascular changes in the supplying artery.
Biomarkers
As yet, there have been no biomarkers identiﬁed as a
useful adjunct to AVF planning. Biomarkers have been ex-
tensively investigated in ESRD patients focusing on their
usefulness in prognosis, diagnostics, response to therapy
and prevention of disease. Elevated ﬁbroblast growth
factor 23 and bone alkaline phosphatase have been
identiﬁed as having prognostic value in predicting mortal-
ity in patient with ESRD-related bone mineral disease
while elevated C-reactive protein, interleukin-6 and
tumour necrosis factor levels are associated with in-
creased mortality in ESRD patients [54]. Asymmetric di-
methylarginine is an endogenous inhibitor of nitric oxide
synthase and high circulating levels are associated with
endothelial dysfunction and atherosclerosis in patients
with pre-dialysis ESRD [55].
A number of inﬂammatory markers, such as interleukin-
6, tumour necrosis factor-α and soluble P selectin, have
been associated with adverse cardiovascular outcomes
[56]; however, high-sensitivity CRP (hs-CRP) has the stron-
gest association with cardiovascular outcomes [57]. It is
reported that hs-CRP can destabilize nitric oxide synthase
mRNA in endothelial cells [58], suggesting a correlation
between high circulating levels of hs-CRP and endothelial
dysfunction. Also, 13-hydroxyoctadecadienoic acid (13-
HODE) has been found to decrease with age in patients
undergoing coronary artery bypass grafting and has been
associated with an increase in endothelial cell thrombo-
genicity [56]. Other surrogate markers of endothelial cell
activation and inﬂammation have been proposed, including
lipoprotein-associated phospholipase A2, CD40 receptor/
CD40 ligand interaction, LOX-1 and direct measurements of
circulating endothelial progenitor cells [59]. Further studies
are required to establish if assessing biomarkers of baseline
endothelial function in patients with ESRD is clinically
useful either for prediction of AVF maturation or to target
therapies to modify local vascular biology prior to AVF
formation.
Creation of an AVF has been shown to have signiﬁcant
effects on atrial natriuretic peptide (ANP) and brain natri-
uretic peptide (BNP). An increase in ANP was induced by
volume loading and BNP release was stimulated by left
ventricular diastolic dysfunction. Additionally, a positive
relationship has been shown between MMP-2 gene ex-
pression in vein segments evaluated by gelatin zymogra-
phy and western blotting and AVF maturation [60]. The
maximal beneﬁt from biomarkers may lie in the multi-
marker approach as evidenced by the Olmsted study
which reported that the combination of increased BNP
with CRP levels enhanced the ability to predict risk of
death compared with standard risk factors for mortality in
heart failure [61].
Advanced glycation end-products (AGEs) have been im-
plicated in the pathophysiology of vascular disease where
they accumulate in the endothelial cell wall and disrupt
cellular structure and function, including decreasing the
bioavailability of nitrous oxide and alteration of cell
surface structure from an anticoagulant to pro-coagulant
state. In theory, reducing the burden of AGEs would offer
a potential novel therapeutic option to improve vascular
biology and potentially improve maturation of AVFs. There
is experimental evidence that agents such as aminogua-
nidine, ALT-946, ALT-711, statins, pyridoxamine and
dietary modiﬁcations can help to reduce AGE levels [62].
There is no convincing evidence yet that such therapies
improve vascular access outcomes.
Assisted maturation
Several novel therapies have been proposed to assist AVF
maturation, including the use of far-infrared (FIR)
therapy [63]. FIR is a non-invasive therapeutic modality
which has been reported to improve access ﬂow rates
and reduce the incidence of AVF malfunction in
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haemodialysis patients. Primary balloon angioplasty has
been shown to improve primary AVF patency rates for
AVFs with venous diameters of <3 mm [64] and also in
AVFs with venous diameters of ≤2 mm [65]. These con-
clusions have been supported by more recent data from
Turmel-Rodrigues, suggesting that by using an aggres-
sive, multi-disciplinary approach a non-maturing AVF can
be identiﬁed, evaluated and salvaged [66]. An increased
number of interventions required to assist maturation is
however associated with reduced primary and secondary
patency rates and a higher number of interventions to
maintain patency [67].
Current studies
The Hemodialysis Fistula Maturation [68] study is currently
underway in the USA. This is a multicentre prospective
cohort study which is aiming to recruit 600 patients under-
going new AVF creation with a 4-year follow-up period.
The primary outcome is unassisted clinical maturation. The
results of this study are eagerly anticipated as this is the
ﬁrst, large-scale, adequately powered cohort to address
many of the outstanding questions related to predictors of
AVF outcomes. Further studies into vascular access out-
comes include the ‘Antiaggregation in Primary Prevention
of Vascular Access for Hemodialysis’ (NCT02055131) and
‘The Use of Glyceryl Trinitrate Patches in Arteriovenous Fis-
tulas’ (NCT01685710) which will provide further informa-
tion on the use of aspirin in varying doses and the use of
glyceryl trinitrate patches applied 5 cm proximal from the
site of vascular access surgery in the prevention of early
stenoses.
Conclusion
The factors leading to failure of AVF maturation are still ill
deﬁned and there is a limited ability to predict surgical
vascular outcomes. Clinical examination and DUS mea-
surements are the mainstays of current preoperative as-
sessment. Further studies into this under-researched ﬁeld
are currently underway and there are many opportunities
to develop better tools to predict AVF outcomes.
Conﬂict of interest statement. None declared.
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